BioPharmSignal logoBioPharmSignal

Biotech News

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

Minerva Neuroscience (NERV)Minerva NeuroscienceCompany update

BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief

Related news

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-06-01 20:05 EST

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

ECORelectroCore2026-06-17 12:00 EST

electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference

BCLIBrainstorm Cell Therapeutics Inc.2026-08-24 12:15 EST

BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

TNXPTonix Pharmaceuticals2026-08-05 11:00 EST

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

PRAXPraxis Precision Medicines2026-06-04 20:01 EST

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

ALKSAlkermes plc2026-06-03 20:05 EST

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

ANNXAnnexon, Inc.2026-05-27 12:00 EST

Annexon to Participate in Upcoming June Investor Conferences

AXSMAxsome2026-05-27 11:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

View all latest news

Minerva Neuroscience

CNS Drug Development Minerva Neurosciences develops therapies for central nervous system disorders. Its lead program focuses specifically on negative symptoms of schizophrenia, an area with limited approved treatment options. Roluperidone Roluperidone is an investigational oral therapy intended to improve primary negative symptoms such...

Recent company news

NERVMinerva Neuroscience2026-08-07 11:00 EST

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-06-01 20:05 EST

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

NERVMinerva Neuroscience2026-05-18 20:05 EST

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

NERVMinerva Neuroscience2026-05-05 12:00 EST

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-04-02 20:05 EST

Minerva Announces Leadership Transition

Stock data

Close
4.84 USD
Market cap
221.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States